Senior Clinical Lecturer and Consultant Neurologist
Magnetic resonance imaging (MRI) is a safe way of investigating people- there is no radiation involved in the scans- and offers a window with which to study disease mechanisms in living patients. This is crucial in neurodegenerative diseases, which remain incompletely understood. MRI also has potential as a biomarker, with which to investigate the effect of new treatments, so important in these currently incurable conditions. I have two main studies active at present. We are investigating the potential of whole-body muscle MRI (example picture attached) as a biomarker in patients with motor nerve disorders. I am also very interested in deficiencies in the way that patients with motor neuron disease use energy and was recently awarded a grant by Neurocare and the Ryder-Briggs Trust to develop MR spectroscopy to assess this further. Lastly, we are collecting scans from patients with motor neuron disorders to contribute to a large multi-centre database to further research at international collaborative level.
I am in the process of establishing a new research project which aims to assess deficits of energy metabolism in patients with MND using MR spectroscopy.
- Jenkins TM, Burness C, Connolly DJ, et al. A prospective pilot study measuring muscle volumetric change in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 2013: In press.
- Jenkins TM, Ciccarelli O, Atzori M, et al. Early pericalcarine atrophy in acute optic neuritis is associated with conversion to MS. J Neurol Neurosurg Psychiatry 2011; 82(9): 1017-1021.
- Jenkins TM, Toosy AT, Ciccarelli O, et al. Neuroplasticity predicts visual recovery in acute optic neuritis independent of tissue damage. Ann Neurol 2010; 67(1): 99-113.
- Jenkins TM, Ciccarelli O, Toosy AT, et al. Dissecting structure-function interactions in acute optic neuritis to investigate neuroplasticity. Hum Brain Mapp 2010; 31(2): 276-286.
- Kolappan M, Henderson AP, Jenkins TM, et al. Assessing structure and function of the afferent visual pathway in multiple sclerosis and associated optic neuritis. J Neurol 2009; 256: 309-319.
I am module lead for Cerebrovascular disease and disorders of consciousness on the MSc course in Clinical Neurology at the University of Sheffield.
I represent the University of Sheffield as a member of the Neuroimaging Society on Amyotrophic Lateral Sclerosis (NiSALS), an international collaboration to forward neuroimaging research in MND.
I qualified as a doctor in 1999 and, after training in general medicine and neurology in Manchester, Blackpool, Perth, Darwin and London, I decided that I wanted to learn to apply neuroimaging techniques to try and better understand neurological diseases. Neuroimaging is a field which has advanced very rapidly in recent years and improvements in technology now allow assessment of many different aspects of disease in a way which is minimally invasive for patients. I obtained my PhD in Clinical Neuroscience from the UCL Institute of Neurology, Queen Square, London and moved to Sheffield in 2009 to complete my training in clinical neurology. I am focusing on establishing a neuroimaging research programme for patients with motor neuron disease (MND) in Sheffield. Outside of work, I enjoy running for Hallamshire Harriers and once came 67th in the London Marathon.
I find teaching one of the most enjoyable parts of my job and I give regular lectures and clinical demonstrations to medical students, nurses, newly qualified doctors, psychiatrists and dentists. The lectures cover a wide range of aspects of clinical neurology, from the features of diseases such as MND, multiple sclerosis and other neurological disorders, through to the neuroanatomical basis of emotions.